ZYLOX-TONBRDG.MED.TECH.H1 (818) - Net Assets
Based on the latest financial reports, ZYLOX-TONBRDG.MED.TECH.H1 (818) has net assets worth €3.15 Billion EUR (≈ $3.69 Billion USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€3.50 Billion ≈ $4.09 Billion USD) and total liabilities (€341.97 Million ≈ $399.80 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Explore 818 operating cash flow to assess how effectively this company generates cash.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €3.15 Billion |
| % of Total Assets | 90.22% |
| Annual Growth Rate | -0.46% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 1.56 |
ZYLOX-TONBRDG.MED.TECH.H1 - Net Assets Trend (2021–2024)
This chart illustrates how ZYLOX-TONBRDG.MED.TECH.H1's net assets have evolved over time, based on quarterly financial data. Also explore 818 total asset value for the complete picture of this company's asset base.
Annual Net Assets for ZYLOX-TONBRDG.MED.TECH.H1 (2021–2024)
The table below shows the annual net assets of ZYLOX-TONBRDG.MED.TECH.H1 from 2021 to 2024. For live valuation and market cap data, see 818 market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €3.10 Billion ≈ $3.63 Billion |
+1.76% |
| 2023-12-31 | €3.05 Billion ≈ $3.56 Billion |
-1.51% |
| 2022-12-31 | €3.09 Billion ≈ $3.62 Billion |
-1.61% |
| 2021-12-31 | €3.14 Billion ≈ $3.68 Billion |
-- |
Equity Component Analysis
This analysis shows how different components contribute to ZYLOX-TONBRDG.MED.TECH.H1's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 35489500000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €65.28 Million | 2.11% |
| Other Components | €3.04 Billion | 97.89% |
| Total Equity | €3.10 Billion | 100.00% |
ZYLOX-TONBRDG.MED.TECH.H1 Competitors by Market Cap
The table below lists competitors of ZYLOX-TONBRDG.MED.TECH.H1 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Mid Penn Bancorp
NASDAQ:MPB
|
$757.41 Million |
|
Van Phu - Invest Investment JSC
VN:VPI
|
$757.56 Million |
|
Harim Holdings Co. Ltd
KQ:003380
|
$757.99 Million |
|
ChengDa Pharmaceuticals Co. Ltd.
SHE:301201
|
$758.20 Million |
|
Sinosteel Luonai Materials Technology Co. Ltd. A
SHG:688119
|
$757.27 Million |
|
Chongqing Constr Engineering
SHG:600939
|
$757.23 Million |
|
NEW HORIZ.HEAL. DL-00005
F:6YZ
|
$757.17 Million |
|
Nuh Cimento Sanayi AS
IS:NUHCM
|
$756.99 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ZYLOX-TONBRDG.MED.TECH.H1's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 3,047,385,000 to 3,101,004,000, a change of 53,619,000 (1.8%).
- Net income of 100,256,000 contributed positively to equity growth.
- Share repurchases of 66,912,000 reduced equity.
- New share issuances of 55,000 increased equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €100.26 Million | +3.23% |
| Share Repurchases | €66.91 Million | -2.16% |
| Share Issuances | €55.00K | +0.0% |
| Other Changes | €20.22 Million | +0.65% |
| Total Change | €- | 1.76% |
Book Value vs Market Value Analysis
This analysis compares ZYLOX-TONBRDG.MED.TECH.H1's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.25x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €9.47 | €2.40 | x |
| 2022-12-31 | €9.37 | €2.40 | x |
| 2023-12-31 | €9.65 | €2.40 | x |
| 2024-12-31 | €9.77 | €2.40 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently ZYLOX-TONBRDG.MED.TECH.H1 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 3.23%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 12.81%
- • Asset Turnover: 0.23x
- • Equity Multiplier: 1.11x
- Recent ROE (3.23%) is above the historical average (-2.34%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -6.35% | -112.24% | 0.05x | 1.03x | €-514.16 Million |
| 2022 | -3.67% | -33.99% | 0.10x | 1.05x | €-422.97 Million |
| 2023 | -2.58% | -14.92% | 0.16x | 1.11x | €-383.47 Million |
| 2024 | 3.23% | 12.81% | 0.23x | 1.11x | €-209.84 Million |
Industry Comparison
This section compares ZYLOX-TONBRDG.MED.TECH.H1's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $37,411,546,005
- Average return on equity (ROE) among peers: -877.09%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ZYLOX-TONBRDG.MED.TECH.H1 (818) | €3.15 Billion | -6.35% | 0.11x | $757.37 Million |
| LEPU MED.T.B. SP.GDR O.N. (07Z0) | $17.50 Billion | 7.19% | 0.43x | $146.67K |
| BIORETEC OY (0TN) | $9.74 Million | -47.38% | 0.18x | $16.10 Million |
| SYSMEX CORP.UNSP.ADR 1/2 (0YX0) | $349.05 Billion | 12.63% | 0.39x | $4.70 Billion |
| INMODE LTD IS -01 (154) | $703.81 Million | 25.76% | 0.12x | $711.77 Million |
| HeraMED Limited (1I4) | $76.93K | -8590.94% | 35.29x | $28.30 Million |
| Medtronic PLC (2M6) | $1.75 Billion | 30.35% | 0.38x | $83.04 Billion |
| Peijia Medical Limited (4WO) | $2.64 Billion | -15.46% | 0.26x | $391.36 Million |
| AVITA Medical Inc (51KB) | $20.86 Million | -118.03% | 0.23x | $172.49 Million |
| BRAINCOOL AB (5YL) | $111.74 Million | -54.84% | 0.19x | $21.56 Million |
| MICROPORT CARDIO.MEDTECH. (72X) | $2.33 Billion | -20.20% | 0.10x | $107.57 Million |
About ZYLOX-TONBRDG.MED.TECH.H1
Zylox-Tonbridge Medical Technology Co., Ltd., a medical device company, provides neuro- and peripheral-vascular interventional medical devices in the People's Republic of China and internationally. The company offers a neurovascular product portfolio that covers a suite of products for various categories, including ischemic stroke, hemorrhagic stroke, intracranial stenosis, carotid artery, and in… Read more